NCE-1 Intelligence & Market Opportunity

Xolremdi

Mavorixafor

Immunomodulators

Oral Capsules

Xolremdi is a once-daily pill that helps people aged 12 years and older with WHIM syndrome by increasing important white blood cells to strengthen the body’s defense against infections.

Approval Date

26-Apr-24

NCE-1 Date

26-Apr-28

NCE Date

26-Apr-29

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

1.3916

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

100

2029

229

2030

416

2031

560

2032

715

Molecule profile

Details & specifications

Molecule

Mavorixafor

Innovator

X4 PHARMACEUTICALS INC

Dosage Form

Oral Capsules

Strength

100 mg

Therapeutic Category

Immunomodulators

Usage

To treat WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis)

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.